Erste Asset Management Gmb H Gilead Sciences, Inc. Transaction History

Erste Asset Management Gmb H

$10.3 Trillion
Q3 2025

A detailed history of Erste Asset Management Gmb H transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 446,842 shares of GILD stock, worth $55.4 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares

446,842

Previous 477,141 6.35%

Holding current value

$55.4 Million

Previous $52.7 Billion 4.58%

% of portfolio

0.49%

Previous 0.44%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$108.22 - $120.47 $3.28 Million - $3.65 Million	-30,299 Reduced 6.35%	446,842 $50.3 Billion
Q2 2025 Aug 14, 2025	BUY	$96.91 - $113.0 $8.05 Million - $9.38 Million	83,048 Added 21.07%	477,141 $52.7 Billion
Q1 2025 May 14, 2025	BUY	$89.14 - $117.41 $206,715 - $272,273	2,319 Added 0.59%	394,093 $44.1 Billion
Q4 2024 Feb 10, 2025	SELL	$83.95 - $97.9 $1.52 Million - $1.77 Million	-18,055 Reduced 4.41%	391,774 $36.9 Billion
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $27.3 Million - $34.4 Million	409,829 New	409,829 $34.3 Billion

Q2 2024 Nov 26, 2024	BUY	$63.15 - $72.88 $175,872 - $202,970	2,785 Added 0.69%	407,654 $28.1 Billion
Q1 2024 Nov 26, 2024	SELL	$71.58 - $87.29 $811,216 - $989,257	-11,333 Reduced 2.72%	404,869 $29.6 Billion
Q4 2023 Nov 26, 2024	BUY	$73.27 - $83.09 $1.92 Million - $2.18 Million	26,249 Added 6.73%	416,202 $33.8 Billion
Q3 2023 Nov 26, 2024	SELL	$73.94 - $80.67 $8.56 Million - $9.34 Million	-115,737 Reduced 22.89%	389,953 $29.4 Billion
Q2 2023 Nov 26, 2024	SELL	$76.01 - $86.7 $6.35 Million - $7.24 Million	-83,502 Reduced 17.78%	386,088 $29.4 Billion
Q1 2023 Nov 26, 2024	BUY	$77.31 - $88.08 $2.16 Million - $2.46 Million	27,878 Added 6.31%	469,590 $38.2 Billion
Q4 2022 Nov 26, 2024	BUY	$62.32 - $89.47 $4.87 Million - $7 Million	78,225 Added 18.3%	505,690 $43.1 Billion
Q3 2022 Nov 26, 2024	BUY	$59.54 - $68.01 $1.9 Million - $2.17 Million	31,883 Added 7.78%	441,712 $27.9 Billion
Q2 2022 Nov 26, 2024	BUY	$57.72 - $65.01 $15.9 Million - $17.9 Million	275,825 Added 181.89%	427,465 $26.7 Billion
Q1 2022 Nov 22, 2024	BUY	$57.92 - $72.58 $1.86 Million - $2.33 Million	32,123 Added 8.39%	415,047 $24.8 Billion
Q4 2021 Nov 22, 2024	BUY	$64.88 - $73.64 $146,563 - $166,352	2,259 Added 0.55%	412,088 $30.3 Billion
Q3 2021 Nov 22, 2024	BUY	$67.69 - $73.03 $756,300 - $815,964	11,173 Added 3.01%	382,924 $27.2 Billion
Q2 2021 Nov 22, 2024	SELL	$63.47 - $69.35 $346,482 - $378,581	-5,459 Reduced 1.45%	371,751 $25.3 Billion
Q1 2021 Nov 22, 2024	BUY	$60.0 - $68.46 $923,400 - $1.05 Million	15,390 Added 4.25%	377,210 $24.7 Billion
Q4 2020 Nov 22, 2024	BUY	$56.65 - $64.55 $592,559 - $675,193	10,460 Added 2.98%	361,820 $20.6 Billion
Q3 2020 Nov 22, 2024	SELL	$62.1 - $78.08 $3.63 Million - $4.57 Million	-58,469 Reduced 14.27%	351,360 $21.8 Billion
Q2 2020 Nov 22, 2024	BUY	$72.34 - $84.0 $5.35 Million - $6.22 Million	74,015 Added 23.56%	388,220 $29.1 Billion
Q1 2020 Nov 22, 2024	BUY	$62.63 - $80.22 $5.92 Million - $7.58 Million	94,495 Added 43.01%	314,205 $23.7 Billion
Q4 2019 Nov 22, 2024	SELL	$61.62 - $67.78 $11.7 Million - $12.9 Million	-190,119 Reduced 46.39%	219,710 $14.5 Billion
Q3 2019 Nov 22, 2024	BUY	$62.51 - $69.0 $94,702 - $104,535	1,515 Added 0.54%	283,455 $17.8 Billion
Q2 2019 Nov 22, 2024	SELL	$61.87 - $69.38 $1.14 Million - $1.28 Million	-18,500 Reduced 6.16%	281,940 $18.9 Billion
Q1 2019 Nov 22, 2024	SELL	$62.53 - $70.05 $6.84 Million - $7.66 Million	-109,389 Reduced 26.69%	300,440 $19.1 Billion
Q4 2018 Nov 26, 2024	SELL	$60.54 - $79.0 $15.6 Million - $20.4 Million	-258,189 Reduced 63.0%	151,640 $9.54 Billion

Others Institutions Holding GILD

# of Institutions

2,372

Shares Held

1.01B

Call Options Held

8.63M

Put Options Held

7.39M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $156B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Account

Erste Asset Management Gmb H Gilead Sciences, Inc. Transaction History